Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Nutrition and supplements for cancer survivors

AACR 2012

31 Mar - 4 Apr 2012

Published: 18 Apr 2012

Views: 11253

Rating:

Save

Prof Susan Mayne - Yale University, Connecticut, USA

Prof Susan Mayne talks about her presentation at the AACR 2012 Annual meeting on the scientific evidence on supplements and nutrition for the growing population of cancer survivors.

ecancerNews Coverage: Supplements and cancer prevention

Related Videos

Nab-paclitaxel as first line treatment of gastrointestinal neuroendocrine...

Dr Lorraine Chantrill - University of Sydney, Sydney, Australia

Nab-paclitaxel as first line treatment of gastrointestinal neuroendocrine carcinomas shows efficacious results ( Dr Lorraine Chantrill - University of Sydney, Sydney, Australia )

Vitamin D in patients with low tumour-burden indolent non-Hodgkin lymphoma...

Dr Jonathan Friedberg - University of Rochester, Rochester, USA

Vitamin D in patients with low tumour-burden indolent non-Hodgkin lymphoma treated with rituximab therapy ( Dr Jonathan Friedberg - University of Rochester, Rochester, USA )

Choosing Wisely conferences: Lessons learned and the way forward

Dr Omar Abdihamid - Garissa Cancer Centre, Garissa, Kenya

Choosing Wisely conferences: Lessons learned and the way forward ( Dr Omar Abdihamid - Garissa Cancer Centre, Garissa, Kenya )

CAR-T therapy and impact to cancer patient outcomes and experience of treatment

Mr Matthias Hellberg-Naegele - Cantonal Hospital St Gallen, St Gallen...

CAR-T therapy and impact to cancer patient outcomes and experience of treatment ( Mr Matthias Hellberg-Naegele - Cantonal Hospital St Gallen, St Gallen, Switzerland )

KEYNOTE-756 trial shows increased response in ER+/HER2- breast cancer

Dr Fatima Cardoso - Champalimaud Cancer Center, Lisbon, Portugal

KEYNOTE-756 trial shows increased response in ER+/HER2- breast cancer ( Dr Fatima Cardoso - Champalimaud Cancer Center, Lisbon, Portugal )

Feasibility and safety of boost at 74 Gy based on interim FDG-PET during...

Prof Gerard Zalcman - Université de Paris, Paris, France

Feasibility and safety of boost at 74 Gy based on interim FDG-PET during thoracic radio-chemotherapy for NSCLC patients ( Prof Gerard Zalcman - Université de Paris, Paris, France )

Neoadjuvant cemiplimab shows favourable event-free, disease-free and overall...

Dr Neil Gross - MD Anderson Cancer Center, Houston, USA

Neoadjuvant cemiplimab shows favourable event-free, disease-free and overall survival rates in patients with resectable CSCC ( Dr Neil Gross - MD Anderson Cancer Center, Houston, USA )

Genomic testing: Awareness and effective communication between healthcare...

Prof Richard Simcock and Antonella Cardone

Genomic testing: Awareness and effective communication between healthcare professionals and patients ( Prof Richard Simcock and Antonella Cardone )

Adagrasib shows durable clinical benefit in advanced KRAS-mutant NSCLC

Dr Shirish Gadgeel - Henry Ford Cancer Institute, Detroit, USA

Adagrasib shows durable clinical benefit in advanced KRAS-mutant NSCLC ( Dr Shirish Gadgeel - Henry Ford Cancer Institute, Detroit, USA )

More from ecancer